Leading IR Consultancy for Emerging Chinese Companies
HAIKOU CITY, Hainan, China, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced the appointment of The Ruth Group (TRG) as its investor relations agency.
Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., commented, "We look forward to working with The Ruth Group as our strategic, full-service investor relations team to enhance the visibility of China Pharma Holdings among the U.S. investment community. The Ruth Group's dedicated focus and expertise within the biopharmaceuticals industry has contributed to its successful track record providing top tier investor relations and public relations counsel for China-based, and healthcare companies. We will partner with TRG to position ourselves as China's premier biopharmaceutical company with a profitable low-cost, high margin business model and diverse, expanding product portfolio driven by the market demands of our region's rapidly growing healthcare industry."
Ms. Carol Ruth, President of The Ruth Group, stated, "We welcome the opportunity to partner with China Pharma Holdings to raise the Company's profile in the U.S. as we have done for emerging Chinese companies, including Sinovac, JA Solar, SINA, and China TechFaith Wireless. Our strategic messages will highlight China Pharma Holdings as a compelling investment opportunity for U.S. value investors looking for profitable biopharmaceutical companies with substantial growth potential. Our location in New York City allows us to maintain close contact with the U.S. healthcare investment community and ensures that our clients meet their information requirements. In addition, our professional staff understands how to close the information gap and be available in Asian time zones to service our clients."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc., develops, manufactures, and markets specialty pharmaceutical products in China that treat a wide range of conditions, including cardiovascular and CNS diseases, infections, digestive diseases and other prevalent diseases. China Pharma Holdings Inc., is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
About The Ruth Group
The Ruth Group (TRG) is a New York City-based full service investor relations and public relations agency providing top-tier counsel, communications strategies and capital markets advisory to emerging healthcare and technology companies. TRG's integrated, targeted outreach efforts leverage the agency's relationships with U.S. investors and media outlets to maximize the impact of positive milestones and enhance visibility for each client. In-depth, sector-specific expertise differentiates TRG from all other agencies through specialized teams dedicated to alternative energy, biopharmaceuticals, healthcare services, internet media, medical technology, and technology. Each team is run by professionals skilled in the areas of finance, corporate communications and science. A broad and growing client base of emerging Chinese clients within each of these sectors demonstrates TRG's success in working through Asian time zones to close the information gap and provide superior service. For more information, please visit http://www.theruthgroup.com .
Safe Harbor Statement: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
Diana Huang
Tel: +86-898-6681-1730
Email: hps@chinapharmaholdings.com
The Ruth Group
Sara Ephraim
Tel: +1-646-536-7002
Email: sephraim@theruthgroup.com
